What are safer alternatives for long-term anxiety or depression treatment?

The evidence retrieved here does not directly compare non-drug alternatives to long-term SSRI use. It covers specific interventions for different populations and contexts, not a head-to-head safety comparison for decades of anxiety or depression treatment.

The strongest non-drug evidence in this retrieval is the IMPACT trial [1]. It tested a collaborative care model—depression care managers, medication monitoring, and brief psychotherapy—in 1,801 older adults. At 24 months, the intervention group had lower depression scores (SCL-20 1.11 vs 1.34) and better quality of life [1]. The number needed to treat for a 50% symptom drop was 9 at 24 months [1]. This is a behavioral and systems-level intervention, not a pill, and it produced persistent benefit even after the active phase ended.

For anxiety specifically, the retrieved evidence on benzodiazepine alternatives is thin. Buspirone, a non-benzodiazepine anxiolytic, is documented as having a different mechanism (5-HT1A partial agonism) and no cross-tolerance with benzodiazepines [5][6]. But no long-term safety or efficacy data for buspirone appears in these records. Pregabalin was studied only as a sleep aid during benzodiazepine withdrawal [2], not as a standalone long-term treatment.

The retrieved evidence on benzodiazepine withdrawal itself is sobering. One trial found that even with structured tapering and paroxetine support, only 13% of long-term users remained benzodiazepine-free at 2.3 years of follow-up [4]. Withdrawal symptoms were universal and severe in a smaller controlled study: peak anxiety at 3–7 days, weight loss, and EEG changes [3]. Cognitive performance improved after withdrawal, but the process was difficult [3].

Maintenance ECT is documented as an option for severe, treatment-resistant depression, with relapse rates as low as 8% when combined with nortriptyline in older psychotic depression [7]. But this is a last-line intervention with cognitive side effects, not a safer alternative for routine long-term use.

The evidence does not answer the question. No retrieved study compares the long-term safety or efficacy of any non-drug intervention—exercise, therapy, diet, supplements—against decades of SSRI use. The IMPACT trial [1] is the closest, and it shows that organized behavioral support works better than usual care over two years. That is a meaningful finding, but it is not a safety comparison.

My call: the evidence for safer long-term alternatives to SSRIs is absent from this retrieval. The IMPACT model [1] is the best-supported non-drug approach for depression in older adults, but no study here tests whether it is safer or more effective than decades of medication. Confidence: low for any specific alternative; moderate for the claim that the question has not been studied in the retrieved literature.